Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
We hypothesize that a simple bridging ARV regimen that tends to select for virus with a low
replicative capacity may tend to stabilize CD4 cell counts and HIV viral load and might be an
option to consider in patients with MDR HIV.
This strategy will provide them with the bridge they desperately need so that they can await
the development of new therapies that when used in combination will give them the best chance
in achieving complete virologic suppression.
Phase:
Phase 1
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore